We design, perform and interpret high resolution proteomics studies to improve target discovery, validation and mechanism of action studies.
Combined tissue and fluid proteomics delivers superior discovery and validation of diagnostic, stratification and pharmacodynamic biomakers.
Appointment of Chief Executive Officer. Dr. Mariola Söhngen has been appointed as a director and Chief Executive Officer. CEO appointment
TMT® used in ground breaking research in COVID-19 - Dr. Christian Münch Webinar
Prof. Steve Gygi's review of TMTpro™. Read more
For Clinical Trial Samples – Scientist.com recently qualified our SRM and TMT-SRM assays as being fit-for-purpose under GCLP accreditation.
New report on growing opportunities for TMT: “Tandem Mass Tag Usage Could Benefit From New Methods, Expanded Applications” available to premium subscribers of GenomeWeb Link here
Landmark paper on Alzheimer's disease molecular pathology published Read more